• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 4:06:25 PM ET
    $EYES
    Industrial Specialties
    Health Care
    Get the next $EYES alert in real time by email
    SC 13G/A 1 eyes-sc13ga_123120.htm AMENDMENT TO FORM SC 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)

     
    Second Sight Medical Products, Inc.
    (Name of Issuer)
     
    Common Stock

    (Title of Class of Securities)

     

    81362J209

    (CUSIP Number)

     
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    Page 2 of 9

     

    CUSIP No. 81362J209    
           
    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
     

     

     

     

     

     

     

    Page 3 of 9

     

    CUSIP No. 81362J209    
           
    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) x

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0

     
    12

    TYPE OF REPORTING PERSON

    PN

     

     

     

     

     

     

     

     

    Page 4 of 9

     

    CUSIP No. 81362J209    

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) x

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0

     
    12

    TYPE OF REPORTING PERSON

    OO

     
     

     

     

     

     

     

     

    Page 5 of 9

     

    CUSIP No. 81362J209    
           

     

    Item 1(a).   Name of Issuer:                                                             Second Sight Medical Products, Inc. (the “Issuer”)
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices:      12744 San Fernando Road, Suite 400 

    Sylmar, California 91342

         
    Item 2(a).  

    Name of Person Filing:  

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP, Altium Capital Management, LLC, and Altium Growth GP, LLC. Altium Growth Fund, LP is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, Altium Growth Fund, LP. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, Altium Growth Fund, LP.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57 Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock
         
    Item 2(e).   CUSIP Number: 81362J209
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

    Page 6 of 9

     

    CUSIP No. 81362J209    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
             
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

       
      As of the close of business on December 31, 2020, each of the Reporting Persons have no beneficial ownership of the Issuer’s Common Stock.

     

     

     

     

    Page 7 of 9

     

    CUSIP No. 81362J209  

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 10, 2021  
           
      Altium Capital Management, LP  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
           
      By: Altium Growth GP, LLC  
      Its: General Partner  
           
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP,  
        LLC  
           
      Altium Growth GP, LLC  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

     

     

     

    Page 8 of 9

     

    EXHIBIT INDEX

     

    EXHIBIT 1:Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

    Members of Group

     

     

     

     

    Get the next $EYES alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EYES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mendelsohn Adam

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      1/23/23 9:13:06 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Makes Brigid

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      1/23/23 9:11:40 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Dwyer Donald

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      1/23/23 9:09:48 PM ET
      $EYES
      Industrial Specialties
      Health Care

    $EYES
    Leadership Updates

    Live Leadership Updates

    See more
    • Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

      Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat

      7/29/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Announces Results of its 2021 Annual Meeting

      Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held May 28, 2021. Second Sight held its annual meeting online due to the COVID-19 pandemic. 60.98% of shareholders were present online or by proxy. Shareholders voted on four proposals: (1) electing six (6) members of the Board of Directors, to serve until the next annual meeting of shareholders in 2022 and until their successors are duly elected and qualified, (2) ratifying the appointment of Gumbiner Savett Inc. as our

      6/1/21 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market

      Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market Aims to create a global leader with potential to treat nearly all forms of blindnessCombined company to trade on Nasdaq and benefit from business and development synergies in the U.S. and EuropeTransaction provides broader access to financing sources to enable the combined company to accelerate the development and commercialization of its productsPixium Vision to remain listed on Euronext Growth and to be the largest shareholder of the new combined company listed on NasdaqTransaction expected to close in late Q1 or the beginning of Q2 2021Conference Call s

      1/6/21 12:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care

    $EYES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Second Sight Medical Products Inc. (Amendment)

      SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

      9/1/22 9:34:58 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by Second Sight Medical Products Inc.

      SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

      8/31/22 6:49:04 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Second Sight Medical Products Inc. (Amendment)

      SC 13D/A - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)

      7/22/22 5:06:56 PM ET
      $EYES
      Industrial Specialties
      Health Care

    $EYES
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EYES
    SEC Filings

    See more

    $EYES
    Financials

    Live finance-specific insights

    See more
    • Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

      Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ:VANI) (the "Company" or "Vivani") announced that trading of the Company's common stock on The Nasdaq Capital Market under the symbol "VANI" will commence today. Vivani is the combination of Nano Precision Medical, Inc. ("NPM") and Second Sight Medical Products, Inc. Closing of the merger was completed and announced yesterday, August 30, 2022. Vivani leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases with high unmet medical need. Vivani has approximately $55 million in cash to advance the development of its portfolio, which includes lead asset N

      8/31/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

      Vivani will be traded under the new ticker (NASDAQ:VANI) Second Sight Medical Products, Inc.(NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc. ("NPM"). NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. In connection with the merger, Second Sight changed its name to Vivani Medical, Inc

      8/30/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

      Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat

      7/29/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      1/6/23 4:04:18 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      12/15/22 4:45:35 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      11/28/22 5:29:22 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

      Nano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight shareholders will own ~23% of the combined company. Second Sight shareholders join NPM shareholders, including AstraZeneca which has been a strategic investor since 2016 Second Sight currently has over $69M to enable the advancement of NPM-119 through clinical proof of concept into a pivotal clinical trial and continued exploration of the visual prosthesis business opportunity Investor Conference Call Scheduled for Tuesday, February 8, 2022,

      2/7/22 4:30:00 PM ET
      $EYES
      Industrial Specialties
      Health Care